The Pancreatic Cancer Action Network (PanCAN) is a United States-based 501(c)(3) charity that funds research, provides patient/caregiver support, conducts community outreach and advocates for increased federal research funding for those affected by pancreatic cancer.
Since the disease is projected to become the second leading cause of cancer-related death in the U.S. around 2020, the organization established a goal, called the "Vision of Progress", to double pancreatic cancer survival by 2020. The nonprofit seeks to fulfill the goal by spreading greater awareness and increasing funds for research to improve the prevention, diagnosis and treatment of pancreatic cancer.
One way PanCAN raises awareness and funds is through the 5K walk/run event, PurpleStride. The events include more than 80,000 participants in nearly 60 communities in the United States, which are organized by local volunteer affiliates.
History
The Pancreatic Cancer Action Network was founded in February 1999 by a group of survivors and caregivers including Pamela Acosta Marquardt, Paula Kim and Terry Lierman. Their first advocacy event, called "Inaugural One Voice Against Cancer", took place in Washington, D.C., in 2000. By 2002, the organization had created 40 volunteer affiliates across the U.S. In 2006, the first international affiliate started in Japan, and the Government Affairs & Advocacy office opened in Washington, D.C.
The Patient Central call center had helped 25,000 patients and caregivers by 2007. They formed the Deadliest Cancers Coalition in 2008 involving other professional organizations. In 2013, their PurpleStride 5K walk/run event raised over $10.5 million with almost 82,000 participants.
The organization initiated Know Your Tumor in 2014, a precision medicine service that uses molecular profiling to give doctors and their patients details about the biology of their tumor to help with treatment choices. In 2015, they launched the Clinical Trial Finder online resource with a directory of U.S. pancreatic cancer clinical trials. Precision Promise was announced in 2016 as the first precision medicine clinical trial to get new therapies to pancreatic cancer patients faster.
From 2008–2016, PanCAN's community events generated more than $87 million for the pancreatic cancer cause. The total research investment of the organization since 2003 is approximately $104 million to date.
PanCAN is headquartered in Manhattan Beach, California, and also staffs a Washington, D.C., and New York City office.
Research
The Pancreatic Cancer Action Network funds grants for biomedical research in order to better understand the causes of pancreatic cancer and to advance its prevention, detection, treatment and cure. The organization offers grants for basic, translational and clinical research in pancreatic cancer to scientists and clinicians at various career levels.
PanCAN has awarded 174 grants to 170 scientists at 64 institutions with a cumulative projected research investment close to $104 million from 2003 to date, inclusive of their Research Grants Program and internal research initiatives.
The organization evaluated grants awarded from 2003 to 2015, which showed 122 grants given to 123 researchers, totaling over $28.2 million. The grantees leveraged the $28.2 million awarded by PanCAN into $311 million in subsequent funding to support their research. The 123 grantees evaluated authored 1,983 articles in peer-reviewed biomedical journals.
In addition to receiving financial support for their research projects, grantees participate in the organization's Community for Progress, which consists of researchers working together to accelerate scientific and medical advances.
PanCAN's Scientific and Medical Advisory Board is composed of leading cancer scientists, clinicians and healthcare professionals from institutions across the United States who specialize in pancreatic cancer. They provide scientific and clinical expertise to guide PanCAN in planning and implementing research initiatives, in-depth information and educational services for patients, their families and caregivers, as well as healthcare professionals.
Advocacy
The Government Affairs & Advocacy office of the Pancreatic Cancer Action Network was established in Washington, D.C., in 2006. As a result of the office’s efforts, Dr. Randy Pausch testified in support of the cause and PanCAN in the House Appropriations Subcommittee on L-HHS in 2008 about the need for increased funding for pancreatic cancer research.